Author Archives: Ankit Mahadevia

Ankit Mahadevia

About Ankit Mahadevia

CEO of Spero Therapeutics

Beyond the CEO: Building An Effective Leadership Team  
March 15, 2018

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC.   The biotech twittersphere recently engaged in very thoughtful debate (resulting in a great piece by

Leave a comment

Hiring:  Using Your Team To Build A Team
June 16, 2017

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much has been said about who and when to hire in this blog (here and here for example), but

Leave a comment

Building A Stronger Ecosystem to Combat Antimicrobial Resistance
September 26, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  Relative to a decade ago, those of us that have spent time finding new ways to outsmart drug-resistant bacteria

Leave a comment

Growth Phase: Avoiding Vertigo During the Ride Up
June 6, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Startup life can be grueling.  It’s an especially gratifying feeling when your data and your investors signal that it’s

Leave a comment

Look Beyond The Headlines: Tackling Ever-Present Challenge Of Antimicrobial Resistance
March 4, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Infectious disease has had an ebb and flow relationship with our general awareness; epidemics such as Zika, Ebola, and

Leave a comment

Building The Pipeline In Small Biotech: Managing Risk And Reward
December 3, 2015

This blog was written by Ankit Mahadevia, CEO at Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. In my experience, looking to the outside world for new pipeline ideas isn’t just the realm of larger companies.   The

Leave a comment

Preparing To Scale Your Biotech Startup
September 22, 2015

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. After many months (or years) of grinding, your science seems to be working, the market is responding to your story,

Leave a comment

Playing The Waiting Game: A Tactical & Spiritual Guide
June 2, 2015

This blog was written by Ankit Mahadevia, co-founder of Spero, Synlogic, and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. The concept of “getting s#it done” is central to our lives as entrepreneurs. With time and capital

Leave a comment

Finding Success In Failing Early: All About Execution
March 18, 2015

In a period of surging optimism for our industry, it’s easy to forget that historically most of the therapeutic projects we undertake don’t make it to the market (see the data here if you absolutely have to remind yourself of

1 Comment

Riding The Biotech Roller Coaster Like A Pro: Some Observations
December 1, 2014

This blog was written by Ankit Mahadevia, Atlas EIR and c0-founder of Spero and Rodin Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. As startup folks we are great at keeping our heads down and looking ahead; this

Leave a comment

Follow The Patients: The Case For Neuroscience And Other “Challenging” Fields
September 11, 2014

This blog was written by Ankit Mahadevia, CBO of Rodin Therapeutics and Spero Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. There’s an ebb and flow in our business around interest in specific therapeutic areas; hot TAs such

Leave a comment

Growing Beyond The Startup Phase: Lessons learned
July 1, 2014

So your biotech startup’s graduated to a Series A financing and your investors believe there’s nothing but champagne and robust clinical data in your future. Some classic analogies are applicable here; you’ve found a way off the island, you’ve defeated

Leave a comment

Building Great Startup Teams In Biotech: A Three Hour Tour
April 18, 2014

Great teams build great companies, and biotech startups are no exception.   I’ve collected a few observations on great teams while collaborating at Atlas on more than half a dozen startups that have made it past the high-risk seed stage

2 Comments